ZyVersa Therapeutics, Inc. ZVSA
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -33.87% | -59.45% | -5.15% | -20.08% | -18.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.16% | -57.10% | -7.29% | -25.78% | -24.13% |
| Operating Income | 39.16% | 57.10% | 7.29% | 25.78% | 24.13% |
| Income Before Tax | 20.54% | 52.37% | -760.25% | 19.71% | 20.16% |
| Income Tax Expenses | -- | 100.00% | -- | -- | -- |
| Earnings from Continuing Operations | 20.54% | 52.27% | -724.79% | 19.99% | 20.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.54% | 52.27% | -724.79% | 19.99% | 20.16% |
| EBIT | 39.16% | 57.10% | 7.29% | 25.78% | 24.13% |
| EBITDA | -- | 57.24% | 7.29% | 25.77% | 24.12% |
| EPS Basic | 69.51% | 88.33% | -5.31% | 86.12% | 83.97% |
| Normalized Basic EPS | 75.35% | 84.88% | 89.32% | 86.07% | 83.98% |
| EPS Diluted | 69.51% | 88.33% | -5.31% | 86.12% | 83.97% |
| Normalized Diluted EPS | 75.35% | 84.88% | 89.32% | 86.07% | 83.98% |
| Average Basic Shares Outstanding | 160.58% | 308.93% | 683.15% | 476.61% | 398.22% |
| Average Diluted Shares Outstanding | 160.58% | 308.93% | 683.15% | 476.61% | 398.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |